GeneDx posted 2Q26 revenue of USD 114.4 million, up 11% year over year; GAAP net loss widened to USD 17.7 million.
Adjusted net income was USD 0.4 million, swinging from an adjusted net loss in 1Q26; GAAP gross margin was 68%.
Exome and genome revenue rose to USD 100.3 million, up 17% year over year; related result volume climbed to 30,785, up 32%.
Cash position and outlook
Cash, cash equivalents, marketable securities and restricted cash totaled USD 133.5 million at June 30, 2026; pro forma cash was about USD 188 million after a Blackstone deal.
Reaffirmed 2026 revenue outlook of USD 475 million to USD 490 million; guided 3Q26 revenue to USD 122 million to USD 124 million.
WGS•
